MedPath

Autologous Blood for Full-thickness Macular Hole

Not Applicable
Terminated
Conditions
Ophthalmopathy
Interventions
Other: Pars-plana vitrectomy
Registration Number
NCT05494229
Lead Sponsor
Omer Othman Abdullah
Brief Summary

Autologous blood for primary and recurrent holes

Detailed Description

Utilizing whole autologous blood for closing both primary and recurrent holes. Here, we apply a drop of the taken whole blood over the hole, and the access blood will be aspirated on the macula with a silicon-tipped active back-flash cannula, to abolish all the possibilities of the fibrinogenic behavior of the whole blood composition, which might cause traction and recurrent hole formation. Therefore, only the hole will be filled with blood. The blood will be taken under completely sterile and aseptic conditions.

The air infusion will be raised after the valve of one of the trocars will be removed, to allow the air current to dry the clot inside the hole rapidly. Then air gas exchange will be performed to allow the clot to remain away from intraocular fluids for one to two weeks and abolish the possibility of the clot being dissolved.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
5
Inclusion Criteria
  • Primary and recurrent holes
Read More
Exclusion Criteria
  • Lamellar and pseudoholes
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Utilizing autologous whole blood for the full thickness macular holePars-plana vitrectomyIt is an interventional study by performing pars-plana vitrectomy
Primary Outcome Measures
NameTimeMethod
Anatomical outcomeThe fourth week post-operatively

OCT

Secondary Outcome Measures
NameTimeMethod
Functional outcomeThe fourth week post-operatively.

Best corrected visual acuity

Trial Locations

Locations (1)

Omer Othman Abdullah

🇮🇶

Erbil, Iraq

© Copyright 2025. All Rights Reserved by MedPath